老年脓毒症精准抗菌治疗的思考

doi:10.3969/j.issn.1003-9198.2025.04.004

摘要/Abstract

摘要： 脓毒症在老年群体中呈现高发病率、高死亡率的特征,已成为重要的公共卫生挑战。及时有效的抗感染治疗是脓毒症治疗的基石。由于老年人器官功能减退、合并症多、基础情况复杂、病人个体异质性强,实现有效的精准抗菌治疗需要在尽可能明确病原菌的基础上把握老年脓毒症的整体特征,根据个体具体情况选择合适的治疗药物并动态监测调整,严格管理药物使用。然而,目前并无统一的脓毒症抗菌治疗标准药物方案,未来需要开发新技术、新药物以改善病人结局。

关键词: 脓毒症, 老年人, 抗菌治疗, 精准医学

Abstract: Sepsis exhibits high morbidity and mortality among the elderly population, posing a significant public health challenge. Timely and effective anti-infective therapy is the cornerstone of sepsis management. Elderly patients, due to the decline in organ function, multiple comorbidities, complex baseline conditions and high individual heterogeneity, need clear pathogen identification and a grasping of the overall characteristics of sepsis to achieve effective and precise antimicrobial therapy. Furthermore,appropriate therapeutic agents should be selected according to individual circumstances with dynamic monitoring and adjustments, and strict medication management should be implemented. Currently, there is no unified standard antimicrobial therapy regimen for sepsis, so the development of new technologies and medicines in the future is necessary to improve patients’ outcomes.

Key words: sepsis, aged, antimicrobial therapy, precision medicine

中图分类号:

R 631

张典, 陈明泉. 老年脓毒症精准抗菌治疗的思考[J]. 实用老年医学, 2025, 39(4): 341-346.

ZHANG Dian, CHEN Mingquan. Considerations on precision antimicrobial therapy for sepsis in the elderly[J]. Practical Geriatrics, 2025, 39(4): 341-346.

参考文献

[1] 民政部,全国老龄办. 2023年度国家老龄事业发展公报[R/OL].(2024-10-12)[2025-02-17].https://www.gov.cn/lianbo/bumen/202410/content_6979487.htm.
[2] SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J].JAMA, 2016,315(8):801-810.
[3] RUDD K E, JOHNSON S C, AGESA K M, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J].Lancet, 2020, 395(10219):200-211.
[4] FLEISCHMANN C, SCHERAG A, ADHIKARI N K J, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J].Am J Respir Crit Care Med, 2016, 193(3):259-272.
[5] WENG L, XU Y, YIN P, et al. National incidence and mortality of hospitalized sepsis in China[J].Crit Care, 2023,27(1):84.
[6] ROWE T A, MCKOY J M. Sepsis in older adults[J].Infect Dis Clin North Am, 2017, 31(4):731-742.
[7] GOTTS J E, MATTHAY M A. Sepsis: pathophysiology and clinical management[J].BMJ, 2016, 353:i1585.
[8] CANCRO M P. Age-associated B cells[J].Annu Rev Immunol, 2020, 38:315-340.
[9] AIELLO A, FARZANEH F, CANDORE G, et al. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention[J].Front Immunol, 2019, 10:2247.
[10]SANTORO A, BIENTINESI E, MONTI D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity?[J].Ageing Res Rev, 2021,71:101422.
[11]刘超, 毛智, 周飞虎. 老年脓毒症的研究进展[J].解放军医学杂志, 2017, 42(6):563-568.
[12]许培, 吴玲玉, 马丽华, 等. 老年重症患者急性皮肤衰竭现状及危险因素分析[J].中华急危重症护理杂志, 2024, 5(5):401-407.
[13]张新超, 温伟, 董士民. 老年脓毒症诊断与治疗中的困难与挑战[J].中国急救医学, 2024, 44(5):376-384.
[14]MARTIN G S, MANNINO D M, EATON S, et al. The epidemiology of sepsis in the United States from 1979 through 2000[J].N Engl J Med, 2003, 348(16):1546-1554.
[15]边素艳, 曹丰, 程庆砾, 等. 感染诱发的老年多器官功能障碍综合征诊治中国专家共识[J].中国实用内科杂志, 2018,38(8):727-738.
[16]GRITTE R B, SOUZA-SIQUEIRA T, RUI C, et al. Why septic patients remain sick after hospital discharge?[J].Front Immunol, 2021, 11:605666.
[17]KINGREN M S, STARR M E, SAITO H. Divergent sepsis pathophysiology in older adults[J].Antioxid Redox Signal, 2021,35(16):1358-1375.
[18]DI BELLA S, ANTONELLO R M, SANSON G, et al. Anaerobic bloodstream infections in Italy (ITANAEROBY): a 5-year retrospective nationwide survey[J].Anaerobe, 2022,75:102583.
[19]HONORATO M O, SOUSA FILHO J T, HONORATO JUNIOR L F B, et al. Atrial fibrillation and sepsis in elderly patients and their associaton with in-hospital mortality[J].Arq Bras Cardiol, 2023, 120(3):e20220295.
[20]SHANKAR-HARI M, SAHA R, WILSON J, et al. Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis[J].Intensive Care Med, 2020, 46(4):619-636.
[21]AMSTERDAM D, OSTROV B E. The impact of the microbiome on immunosenescence[J].Immunol Invest, 2018,47(8):801-811.
[22]GAO H, NEPOVIMOVA E, ADAM V, et al. Age-associated changes in innate and adaptive immunity: role of the gut microbiota[J].Front Immunol, 2024, 15:1421062.
[23]DESHMUKH H S, LIU Y, MENKITI O R, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice[J].Nat Med, 2014,20(5):524-530.
[24]关万涛. 老年肺炎相关性脓毒症临床特征及影响因素[J].中国老年学杂志, 2020, 40(1):89-92.
[25]LEIBOVICI-WEISSMAN Y, TAU N, YAHAV D. Bloodstream infections in the elderly: what is the real goal?[J].Aging Clin Exp Res, 2021, 33(4):1101-1112.
[26]TANG F, YUAN H, LI X, et al. Effect of delayed antibiotic use on mortality outcomes in patients with sepsis or septic shock: a systematic review and meta-analysis[J].Int Immunopharmacol, 2024, 129:111616.
[27]EVANS L, RHODES A, ALHAZZANI W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J].Intensive Care Med, 2021,47(11):1181-1247.
[28]KLOMPAS M, RHEE C. Antibiotics: it is all about timing, isn’t it?[J].Curr Opin Crit Care, 2022, 28(5):513-521.
[29]KARAKIKE E, GIAMARELLOS-BOURBOULIS E J, KYPRIANOU M, et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis[J].Crit Care Med, 2021, 49(12):2042-2057.
[30]PSARRAKIS C, GIAMARELLOS-BOURBOULIS E J. Advancements in the pharmacological management of sepsis in the elderly[J].Expert Opin Pharmacother, 2023, 24(10):1171-1187.
[31]宁永忠, 王辉. 病毒性脓毒症的流行病学和处置[J].中华医院感染学杂志, 2018, 28(10):1446-1449.
[32]张璐, 李响, 夏世宏, 等. 脓毒症休克的诊治在精准医学时代下的发展及临床应用[J].中华重症医学电子杂志: 网络版, 2021, 7(2):169-173.
[33]PAK T R, RHEE C, KLOMPAS M. Timing and spectrum of antibiotic treatment for suspected sepsis and septic shock: why so controversial?[J].Infect Dis Clin North Am, 2022,36(4):719-733.
[34]BRANDENBURG K, FERRER-ESPADA R, MARTINEZ-DE-TEJADA G, et al. A comparison between SARS-CoV-2 and gram-negative bacteria-induced hyperinflammation and sepsis[J].Int J Mol Sci, 2023, 24(20):15169.
[35]THORNDIKE J, KOLLEF M H. Culture-negative sepsis[J].Curr Opin Crit Care, 2020, 26(5):473-477.
[36]LANDERSDORFER C B, NATION R L. Key challenges in providing effective antibiotic therapy for critically ill patients with bacterial sepsis and septic shock[J].Clin Pharmacol Ther, 2021, 109(4):892-904.
[37]ALLEN J M, SURAJBALI D, NGUYEN D Q, et al. Impact of piperacillin-tazobactam dosing in septic shock patients using real-world evidence: an observational, retrospective cohort study[J].Ann Pharmacother, 2023, 57(6):653-661.
[38]LANCKOHR C, BRACHT H. Antimicrobial stewardship[J].Curr Opin Crit Care, 2022, 28(5):551-556.
[39]VAN DER POLL T. Immunotherapy of sepsis[J].Lancet Infect Dis, 2001, 1(3):165-174.
[40]ROBERTS J A, ABDUL-AZIZ M H, LIPMAN J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions[J].Lancet Infect Dis, 2014, 14(6):498-509.
[41]ULLDEMOLINS M, ROBERTS J A, RELLO J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients[J].Clin Pharmacokinet, 2011,50(2):99-110.
[42]PLATA-MENCHACA E P, FERRER R, RUIZ RODRÍGUEZ J C, et al. Antibiotic treatment in patients with sepsis: a narrative review[J].Hosp Pract, 2022, 50(3):203-213.
[43]DE LA FUENTE-NUNEZ C, CESARO A, HANCOCK R E W. Antibiotic failure: beyond antimicrobial resistance[J].Drug Resist Updat, 2023, 71:101012.
[44]TONG S Y C, LYE D C, YAHAV D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial[J].JAMA, 2020, 323(6):527-537.
[45]FAIX J D. Biomarkers of sepsis[J].Crit Rev Clin Lab Sci, 2013, 50(1):23-36.
[46]VELISSARIS D, ZAREIFOPOULOS N, LAGADINOU M, et al. Procalcitonin and sepsis in the emergency department: an update[J].Eur Rev Med Pharmacol Sci, 2021,25(1):466-479.
[47]HANEY E F, HANCOCK R E W. Addressing antibiotic failure: beyond genetically encoded antimicrobial resistance[J].Front Drug Discov, 2022, 2:892975.
[48]汪浪, 张智琪, 沈雪, 等. 老年脓毒症患者临床特征及预后影响因素[J].中国感染控制杂志, 2022, 21(4):377-383.
[49]中国医疗保健国际交流促进会急诊医学分会, 中华医学会急诊医学分会,中国老年学会基础与转化医学分会.老年急危重症容量管理急诊专家共识[J].中国急救医学, 2024, 44(6):461-472.
[50]YANG J, LIU S, LU J, et al. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria[J].Crit Care, 2022, 26(1):320.
[51]BROOKS B D, BROOKS A E. Therapeutic strategies to combat antibiotic resistance[J].Adv Drug DelivRev, 2014, 78:14-27.
[52]JENSEN P Ø, MØLLER S A, LERCHE C J, et al. Improving antibiotic treatment of bacterial biofilm by hyperbaric oxygen therapy: not just hot air[J].Biofilm, 2019, 1:100008.
[53]刘娟, 左园弋, 康俊杰, 等. 右美托咪定联合咪达唑仑镇静方案在老年脓毒症通气治疗中的应用[J].中国老年学杂志, 2024, 44(5):1069-1071.
[54]MILLER W D, KESKEY R, ALVERDY J C. Sepsis and the microbiome: a vicious cycle[J].J Infect Dis, 2021, 223(12Suppl 2):S264-S269.
[55]ZHAO W J, LIU G E, TIAN Y, et al. What’s new in trauma 2020[J].Chin J Traumatol, 2021, 24(2):63-68.
[56]DULHUNTY J M, BRETT S J, DE WAELE J J, et al. Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial[J].JAMA, 2024, 332(8):629-637.
[57]JONES A E, SHAPIRO N I, TRZECIAK S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial[J].JAMA, 2010,303(8):739-746.
[58]CHEN H, XU J, WANG X, et al. Early lactate-guided resuscitation of elderly septic patients[J].J Intensive Care Med, 2022, 37(5):686-692.
[59]SEVRANSKY J E, ROTHMAN R E, HAGER D N, et al. Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial[J].JAMA, 2021,325(8):742-750.
[60]HUANG M, CAI S, SU J. The pathogenesis of sepsis and potential therapeutic targets[J].Int J Mol Sci, 2019,20(21):5376.
[61]VINCENT J L. Current sepsis therapeutics[J].EBioMedicine, 2022, 86:104318.
[62]HOTCHKISS R S, MONNERET G, PAYEN D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J].Nat Rev Immunol, 2013,13(12):862-874.
[63]ZRELOVS N, KURBATSKA V, RUDEVICA Z, et al. Sorting out the superbugs: potential of sortase A inhibitors among other antimicrobial strategies to tackle the problem of antibiotic resistance[J].Antibiotics, 2021, 10(2):164.